Stock Research for AKRX

AKRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AKRX Stock Chart & Research Data

The AKRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AKRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AKRX Due diligence Resources & Stock Charts

The AKRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AKRX Detailed Price Forecast - CNN Money CNN View AKRX Detailed Summary - Google Finance
Yahoo View AKRX Detailed Summary - Yahoo! Finance Zacks View AKRX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View AKRX Trends & Analysis - Trade-Ideas Barrons View AKRX Major Holders - Barrons
NASDAQ View AKRX Call Transcripts - NASDAQ Seeking View AKRX Breaking News & Analysis - Seeking Alpha
Spotlight View AKRX Annual Report - CompanySpotlight.com OTC Report View AKRX OTC Short Report - OTCShortReport.com
TradeKing View AKRX Fundamentals - TradeKing Charts View AKRX SEC Filings - Bar Chart
WSJ View Historical Prices for AKRX - The WSJ Morningstar View Performance/Total Return for AKRX - Morningstar
MarketWatch View the Analyst Estimates for AKRX - MarketWatch CNBC View the Earnings History for AKRX - CNBC
StockMarketWatch View the AKRX Earnings - StockMarketWatch MacroAxis View AKRX Buy or Sell Recommendations - MacroAxis
Bullish View the AKRX Bullish Patterns - American Bulls Short Pains View AKRX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View AKRX Stock Mentions - StockTwits PennyStocks View AKRX Stock Mentions - PennyStockTweets
Twitter View AKRX Stock Mentions - Twitter Invest Hub View AKRX Investment Forum News - Investor Hub
Yahoo View AKRX Stock Mentions - Yahoo! Message Board Seeking Alpha View AKRX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for AKRX - SECform4.com Insider Cow View Insider Transactions for AKRX - Insider Cow
CNBC View AKRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AKRX - OTC Markets
Yahoo View Insider Transactions for AKRX - Yahoo! Finance NASDAQ View Institutional Holdings for AKRX - NASDAQ


Stock Charts

FinViz View AKRX Stock Insight & Charts - FinViz.com StockCharts View AKRX Investment Charts - StockCharts.com
BarChart View AKRX Stock Overview & Charts - BarChart Trading View View AKRX User Generated Charts - Trading View




Latest Financial News for AKRX


Akorn, Inc. -- Moody's downgrades Akorn's ratings to Caa1; outlook revised to negative
Posted on Friday December 14, 2018

Moody's Investors Service ("Moody's") downgraded the ratings of Akorn, Inc. ("Akorn") including the Corporate Family Rating to Caa1 from B3, the Probability of Default Rating to Caa1-PD from B3-PD and the senior secured term loan rating to Caa1 from B3. Moody's also downgraded the Speculative Grade Liquidity Rating to SGL-3 from SGL-2.


Robbins Arroyo LLP: Shareholder Lawsuit Filed Against Officers and Directors of Akorn, Inc. (AKRX)
Posted on Monday December 10, 2018

Shareholder rights law firm Robbins Arroyo LLP reminds investors that a shareholder of Akorn, Inc. (AKRX) has filed a shareholder lawsuit against the company's officers and directors for breaches of fiduciary duty from 2014 through the present. Akorn is a specialty generic pharmaceutical company. According to the complaint, on April 24, 2017, Fresenius SE Co. KGaA ("Fresenius") agreed to acquire Akorn in a deal valued at $4.3 billion.


After court case loss, drug maker Akorn's CEO will step down
Posted on Monday December 10, 2018

After losing a court case in Delaware last week, the CEO of drug company Akorn Inc. will step down. Last week the Supreme Court of the State of Delaware upheld a lower court’s decision to allow Fresenius Kabi AG to terminate its April 2017 $4.3 billion merger deal with Lake Forest, Illinois-based Akorn. After the court loss was announced, Akorn said CEO Raj Rai will retire.


Is Akorn, Inc. (AKRX) A Good Stock To Buy?
Posted on Sunday December 09, 2018

Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]


Stock Market & Investing Books

Enter a stock symbol to view the stock details.